TCM
CTKB icon

Topline Capital Management’s Cytek Biosciences CTKB Stock Holding History

Topline Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8M Sell
6,283,450
-781,031
-11% -$3.33M 7.22% 6
2026
Q1 		$30.9M Sell
7,064,481
-377,985
-5% -$1.78M 5.1% 7
2025
Q4 		$37.6M Buy
7,442,466
+498,186
+7% +$2.31M 3.4% 10
2025
Q3 		$24.1M Buy
6,944,280
+1,713,020
+33% +$6.43M 4.14% 9
2025
Q2 		$17.8M Buy
5,231,260
+3,760,485
+256% +$12.5M 3.05% 12
2025
Q1 		$5.9M Buy
1,470,775
+1,234,179
+522% +$6.4M 1.35% 18
2024
Q4 		$1.54M Buy
+236,596
New +$1.41M 0.29% 29

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Topline Capital Management's CTKB Position: Q2 2026 in Review

Topline Capital Management reduced its Cytek Biosciences (CTKB) stake by 11% in Q2 2026, selling an estimated $3.33M and leaving 6,283,450 shares worth $27.8M. The position accounts for 7.22% of the portfolio, ranked #6.

Topline Capital Management first reported a position in CTKB in Q4 2024 and has held it in 7 quarters since. The position peaked at $37.6M in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Topline Capital Management held 6,283,450 shares of Cytek Biosciences worth $27.8M as of Q2 2026.
  • Topline Capital Management sold 781,031 Cytek Biosciences shares in Q2 2026, an estimated $3.33M.
  • Cytek Biosciences made up 7.22% of Topline Capital Management's portfolio in Q2 2026, its #6 holding.
  • Topline Capital Management first reported a position in Cytek Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Topline Capital Management's Cytek Biosciences position peaked at $37.6M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Topline Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.